58
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Correlation of microalbumin and sialic acid with anthropometric variables in type 2 diabetic patients with and without nephropathy

, , , , , , , & show all
Pages 243-247 | Published online: 28 Dec 2022

References

  • AbdellaNAkanjiAMojiminiyiORelationship of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabeticsDiabetes Research and Clinical Practic2000506572
  • BrowningLMJebbSAMishraGDElevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in womenInt J Obes Relat200428100410
  • CrookMAPickupJCLumbPJRelationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetesDiabetes Care2001243162211213885
  • CrookMAGoldsmithLAmeerallyPSerum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucoseAnn Clin Biochem200239606812564845
  • ChenJGallMYokoyamaHRaised serum silaic acid in NIDDM patients with and without diabetic nephropathyDiabetes Care199619130348718432
  • CrookMEarleMorocuttiASerum sialic acid a risk factor for cardiovascular disease is increased in IDDM patients with microalbuminuria and clinical proteinuriaDiabetes Care199417305108026286
  • CrookMTuttPPickupJCElevated serum sialic acid concentrations in NIDDM and its relationship to blood pressure and retinopathyDiabetes Care19931657608422833
  • DuncanBBSchmidtMPankowJSLow grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities studyADA2003521799805
  • EnglishPWilliamsGType 2 diabetes. London, Martin Dunitz LtdAnnNY Acad Sci2001106744853
  • FavierFJaussentIMoullecNPrevalence of Type 2 diabetes and central adiposity in La Reunion IslandDiabetes Metab Res Rev200522112
  • HaffnerSGreenbergAWestonWEffect of Rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetesAHA200210667984
  • LindbergGEklundGAGullbergBSerum sialic acid concentration and cardiovascular mortalityBr Med J1991302143461995133
  • LindbergGIsoHRastumLserum sialic acid and its correlate in community samples from Akita, Japan and Minneapolis, USAInt J Epidemiol19972658639126503
  • MelajarviNGyllingHMiettinenTSialic acids and the metabolism of low density lipoproteinJ Lipid Res1996371625318864946
  • NayakSBhakthaGRelationship between sialic acid and metabolic variables in Indian type 2 diabetic patientsLipid Health Dis200541519
  • PickupJCInflammation and activated innate immunity in the pathogenesis of type 2 diabetesDiabetes Care2004278132314988310
  • RazISharfrirESDiabetes: from research to diagnosis and treatment”2003Taylor and Francis Ltd
  • TravingCSchaverRStructure and function and metabolism of diabetic control and complicationsCell Mol Life Sci1998541330499893709
  • PhillipMHPrevention of progression in diabetic nephropathyDiabetes Spectrum2006191824
  • WinzlerRTGlickDTDetermination of serum glycoproteinsMethods of Biochemical analysis1955IINew YorkInterscience Publishers, Inc298
  • WelbornTADhaliwalSSBennettSAWaist – hip ratio is the dominant risk factor predicting cardiovascular death in AustraliaMed J Aus200317958085
  • YaremaKThe sialic acid pathway in human cells2006BaltimoreJohn Hopkins University
  • YokoyamaHJensenJMyrupBRaised serum sialic acid concentration precedes onset of microalbuminuria in IDDMDiabetes Care199619435408732705